Syndax Pharmaceuticals (FRA:1T3) Short Interest


FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
25 GF Score
Price €17.43
! 7 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:1T3 vs CAPR, SLS, AGIO: Short Interest Comparison

For the Biotechnology subindustry, Syndax Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syndax Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Short Interest falls into.


FRA:1T3
25GF Score
Syndax Pharmaceuticals Inc FRA:1T3
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score

Get the complete analysis for FRA:1T3

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.43
Price